Results 31 to 40 of about 62,672 (281)

Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study

Journal of Pharmaceutical Policy and Practice, 2022
Background Upon the authorization of COVID-19 vaccines worldwide, national and international standards were developed to help integrate mass COVID-19 immunization campaigns into the healthcare network.
Abeer Zeitoun, Souheil Hallit, Maya Helali, Sirine Chehade, Carla Allam, Aya Ibrahim, Hani Dimassi, Rita Karam   +7 more
doaj   +1 more source

Electronic health records to facilitate clinical research [PDF]

, 2016
Electronic health records (EHRs) provide opportunities to enhance patient care, embed performance measures in clinical practice, and facilitate clinical research. Concerns have been raised about the increasing recruitment challenges in trials, burdensome
Blomster, Juuso I., Cowie, Martin R., Curtis, Lesley H., Duclaux, Sylvie, Ford, Ian, Fritz, Fleur, Goldman, Samantha, Janmohamed, Salim, Kreuzer, Jörg, Leenay, Mark, Michel, Alexander, Ong, Seleen, Pell, Jill P., Southworth, Mary Ross, Stough, Wendy Gattis, Thoenes, Martin, Zalewski, Andrew, Zannad, Faiez   +17 more
core   +2 more sources

Results of a Sociological Survey on the Needs of Drug Safety Monitoring Specialists for Information on the Creation of the Pharmacovigilance System Master File

Безопасность и риск фармакотерапии, 2020
The Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union oblige developers and marketing authorisation holders to implement a pharmacovigilance system that has to be described in the pharmacovigilance system master file (PSMF ...
N. G. Goloenko, R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, M. V. Protsenko, D. G. Karapetyan   +5 more
doaj   +1 more source

Pharmacovigilance [Pharmacovigilance update]

, 2021
The main pharmacovigilance updates in 2020 are reviewed. Remdesivir in COVID-19: relatively safe but turns out to be less effective than expected. Hydroxychloroquine in COVID-19 : lack of efficacy and risk of arrhythmias. Cytokines storm in COVID-19: may impact pharmacokinetics. VEGF inhibitors: risk of aneurysm and artery dissection. Tofacitinib: dose-
Ekobena, P., Ivanyuk, A., Livio, F.
openaire   +1 more source

Multi-Task Pharmacovigilance Mining from Social Media Posts

, 2018
Social media has grown to be a crucial information source for pharmacovigilance studies where an increasing number of people post adverse reactions to medical drugs that are previously unreported.
Chowdhury, Shaika, Yu, Philip S., Zhang, Chenwei   +2 more
core   +1 more source

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study

Vaccines, 2023
Although the safety profiles of mRNA COVID-19 vaccines (mRNA-1273 and BNT162b2) were evaluated in pre-authorization clinical trials, real-world data allow us to better define their benefit/risk ratio in the paediatric population.
Alessia Zinzi, Mario Gaio, Valerio Liguori, Rosanna Ruggiero, Marina Tesorone, Francesco Rossi, Concetta Rafaniello, Annalisa Capuano   +7 more
doaj   +1 more source

Need for the Development of Dialectical Thinking in Pharmaceutical Personnel to Improve Their Performance in the Pharmacovigilance System

Безопасность и риск фармакотерапии, 2022
The pharmacovigilance system aimed at ensuring the safety of medicines has been functioning in Russia since 1997. However, at the moment, an important part of this system, pharmacy organisations, is not sufficiently involved in pharmacovigilance ...
A. E. Krasheninnikov, B. K. Romanov, R. S. Safiullin, N. V. Shestakov   +3 more
doaj   +1 more source

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age. Overview from European Medicines Agency and European Headache Federation [PDF]

, 2018
Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in the main European Guidelines ...
Dogne, Jean-Michel, Garcia Burgos, Juan, Girard, Thomas, Martelletti, Paolo, Straus, Sabine, Vatzaki, Efstratia   +5 more
core   +2 more sources

Is there a potential of misuse for venlafaxine and bupropion? [PDF]

, 2018
© 2018 Schifano and Chiappini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the ...
Anderson, Augustin, Baker, Baribeau, Bolden-Watson, Campagne, Carvalho, Chiappini, Chiappini, Chouinard, Cosci, Cutler, Deluca, Evans, Fava, Fava, Fountain, Francesconi, Groot, Harvey, Harvey, Hill, Hilliard, Holland, Hopper, Hu, Kantor, Kelly, Khurshid, Kim, Koga, Kotzalidis, Langguth, Lewin, Llorca, Maj, McCormick, Muth, Nelson, Orsolini, Parker, Phillips, Quaglio, Redrobe, Reeves, Renoir, Rettew, Rudolph, Sabljić, Schifano, Schifano, Shang, Shenouda, Sir, Stahl, Stahl, Stahl, Stall, Stassinos, Taylor, Vento, Weikop, Welsh, Wilson, Yoon   +64 more
core   +3 more sources

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source